D Neofytos1, D Ostrander1, S Shoham1, M Laverdiere2, J Hiemenz3, H Nguyen4, W Clarke1, L Brass1, N Lu1, K A Marr1. 1. School of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA. 2. Hopital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada. 3. University of Florida, Gaineville, Florida, USA. 4. University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND:Voriconazole (VOR) levels are highly variable, with potential implications to both efficacy and safety. We hypothesized that VOR therapeutic drug monitoring (TDM) will decrease the incidence of treatment failures and adverse events (AEs). METHODS: We initiated a prospective, randomized, non-blinded multicenter study to compare clinical outcomes in adult patients randomized tostandard dosing (clinician-driven) vs. TDM (doses adjusted based on levels). VOR trough levels were obtained on day 5, 14, 28, and 42 (or at completion of drug; ± 3 days). Real-time dose adjustments were made to maintain a range between 1-5 μg/mL on the TDM-arm, while levels were assessed retrospectively in the standard-arm. Patient questionnaires were administered to assess subjective AEs. RESULTS: The study was discontinued prematurely, after 29 patients were enrolled. Seventeen (58.6%) patients experienced 38 AEs: visual changes (22/38, 57.9%), neurological symptoms (13/38, 34.2%), and liver abnormalities (3/38, 7.9%). VOR was discontinued in 7 (25%) patients because of an AE (4 standard-arm, 3 TDM-arm). VOR levels were frequently out of range in the standard-arm (8 tests >5 μg/mL; 9 tests <1 μg/mL). Three dose changes occurred in the TDM-arm for VOR levels <1 μg/mL. Levels decreased over time in the standard-arm, with mean VOR levels lower at end of therapy compared to TDM (1.3 vs. 4.6 μg/mL, P = 0.008). CONCLUSIONS:VOR TDM has become widespread clinical practice, based on known variability in drug levels, which impaired accrual in this study. Although comparative conclusions are limited, observations of variability and waning levels over time support TDM.
RCT Entities:
BACKGROUND:Voriconazole (VOR) levels are highly variable, with potential implications to both efficacy and safety. We hypothesized that VOR therapeutic drug monitoring (TDM) will decrease the incidence of treatment failures and adverse events (AEs). METHODS: We initiated a prospective, randomized, non-blinded multicenter study to compare clinical outcomes in adult patients randomized to standard dosing (clinician-driven) vs. TDM (doses adjusted based on levels). VOR trough levels were obtained on day 5, 14, 28, and 42 (or at completion of drug; ± 3 days). Real-time dose adjustments were made to maintain a range between 1-5 μg/mL on the TDM-arm, while levels were assessed retrospectively in the standard-arm. Patient questionnaires were administered to assess subjective AEs. RESULTS: The study was discontinued prematurely, after 29 patients were enrolled. Seventeen (58.6%) patients experienced 38 AEs: visual changes (22/38, 57.9%), neurological symptoms (13/38, 34.2%), and liver abnormalities (3/38, 7.9%). VOR was discontinued in 7 (25%) patients because of an AE (4 standard-arm, 3 TDM-arm). VOR levels were frequently out of range in the standard-arm (8 tests >5 μg/mL; 9 tests <1 μg/mL). Three dose changes occurred in the TDM-arm for VOR levels <1 μg/mL. Levels decreased over time in the standard-arm, with mean VOR levels lower at end of therapy compared to TDM (1.3 vs. 4.6 μg/mL, P = 0.008). CONCLUSIONS: VOR TDM has become widespread clinical practice, based on known variability in drug levels, which impaired accrual in this study. Although comparative conclusions are limited, observations of variability and waning levels over time support TDM.
Authors: Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079
Authors: B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges Journal: Lancet Date: 2005 Oct 22-28 Impact factor: 79.321
Authors: R Ally; D Schürmann; W Kreisel; G Carosi; K Aguirrebengoa; B Dupont; M Hodges; P Troke; A J Romero Journal: Clin Infect Dis Date: 2001-09-26 Impact factor: 9.079
Authors: Michael J Dolton; Gerd Mikus; Johanna Weiss; John E Ray; Andrew J McLachlan Journal: J Antimicrob Chemother Date: 2014-02-18 Impact factor: 5.790
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Imke H Bartelink; Tom Wolfs; Martine Jonker; Marjolein de Waal; Toine C G Egberts; Tessa T Ververs; Jaap J Boelens; Marc Bierings Journal: Antimicrob Agents Chemother Date: 2012-10-31 Impact factor: 5.191
Authors: Marjolijn J P van Wanrooy; Lambert F R Span; Michael G G Rodgers; Edwin R van den Heuvel; Donald R A Uges; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2014-09-15 Impact factor: 5.191
Authors: Evan Li; Chu-Lin Tsai; Zahida K Maskatia; Ekta Kakkar; Paul Porter; Roger D Rossen; Sarah Perusich; John M Knight; Farrah Kheradmand; David B Corry Journal: Immun Inflamm Dis Date: 2018-03-25